Pyxis Oncology Inc Total Liabilities
Pyxis Oncology Inc total liabilities. Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has total liabilities worth $36.83 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pyxis Oncology Inc (PYXS) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pyxis Oncology Inc (2019–2024)
Total liabilities of Pyxis Oncology Inc from 2019 to 2024. This chart illustrates how Pyxis Oncology Inc's total liabilities have evolved over time, based on quarterly financial data.
Pyxis Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Pyxis Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Julong Holding Limited Class A Ordinary Shares
NASDAQ:JLHL
|
USA | $317.37 Million |
|
Fabryki Mebli Forte S.A.
WAR:FTE
|
Poland | zł495.26 Million |
|
Positivo Tecnologia S.A
SA:POSI3
|
Brazil | R$2.84 Billion |
|
Great Boulder Resources Ltd
AU:GBR
|
Australia | AU$1.84 Million |
|
Lotte Himart
KO:071840
|
Korea | ₩967.89 Billion |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
USA | $12.90 Million |
|
Cj Corp Pref
KO:001045
|
Korea | ₩29.95 Trillion |
|
IBI Lion SOCIMI S.A.
MC:YIBI
|
Spain | €54.88 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Pyxis Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PYXS total assets.
Liquidity & Leverage Metrics
Pyxis Oncology Inc Total Liabilities Ratios Explained
Pyxis Oncology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pyxis Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pyxis Oncology Inc (2019–2024)
The table below shows the annual total liabilities of Pyxis Oncology Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.43 Million | -24.14% |
| 2023-12-31 | $48.02 Million | -5.01% |
| 2022-12-31 | $50.55 Million | +170.23% |
| 2021-12-31 | $18.71 Million | -27.48% |
| 2020-12-31 | $25.80 Million | +13.73% |
| 2019-12-31 | $22.68 Million | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more